Basilea Pharmaceutica International Ltd.

Blacksmith Medicines Advances Novel Antibiotic FG-2101 Targeting Drug-Resistant Gram-Negative Bacteria

- Blacksmith Medicines' FG-2101 represents a first-in-class non-hydroxamate inhibitor targeting LpxC, a zinc-dependent metalloenzyme found exclusively in Gram-negative bacteria. - The antibiotic candidate has completed IND-enabling studies and is positioned to enter human trials later this year for treating drug-resistant Gram-negative infections. - FG-2101's novel mechanism spares beneficial Gram-positive bacteria in the gut microbiome, potentially reducing C. difficile infection risk compared to broad-spectrum antibiotics. - The compound addresses a critical unmet medical need, as no approved therapeutics currently target LpxC despite its attractiveness as an antibiotic target.